- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02246907
Exercise and Quality of Life in Leukemia Patients (EQUAL)
Effects of Exercise on Patient Reported Outcomes in Newly Diagnosed Adults With Acute Leukemia During Induction Treatment: Exercise and Quality of Life in Leukemia Patients (EQUAL)
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- University of North Carolina Lineberger Comprehenisive Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Newly diagnosed with acute leukemia by pathology report
- Admitted for induction chemotherapy within in the previous 96 hours or +/- 3 days from initiation of induction chemotherapy
- An expected hospital stay of 3-4 weeks or longer
- Participation in the study must be approved by the physician directly responsible for the patient's care while at University of North Carolina -Hospitals
- Age >21 years of age
- Willing and able to provide, signed informed consent
- Willing and able to use a computer to complete study questionnaires
- Ability to understand and speak English
Exclusion Criteria:
The criteria below will be determined by the patient's physician and a review of the patient's medical history. If any of the exclusion criteria are observed, the patients will be informed and excluded from participating in the study.
Participation in this study will involve the same risks as any exercise regimen. Given the potential risks involved, patients will be screened for exclusion based upon the following criteria:
- Cardiovascular disease (unless the disease would not compromise the patient's ability to participate in the exercise rehabilitation program)
- Acute or chronic respiratory disease that would compromise the patient's ability to participate in the exercise rehabilitation program
- Acute or chronic bone, joint, or muscular abnormalities that would compromise the patient's ability to participate in the exercise rehabilitation program
- Inability to understand and speak English
- Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent
- Another active malignancy
- Patients will also be excluded if they have active bleeding, acute thrombosis, ischemia, hemodynamically unstable, and uncontrolled pain.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: SUPPORTIVE_CARE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Control Group
The control group will receive standard of care which includes recreational therapy and standard encouragement.
|
|
|
Other: Exercise
Participants in this arm will receive standard of care plus exercise for the duration of their inpatient stay for induction chemotherapy.
|
All intervention patients will participate in an individualized prescriptive exercise intervention 2 to 4 times per week for a period of the induction chemotherapy/in-hospital recovery.
The exercise intervention will begin on week 1 of the study, the day after the first batteries of initial assessments are concluded.
Each exercise session will be divided into two parts.
One part will be administered in the morning and the second one late in the afternoon.
There will be a period of rest of at least 36 hours between each exercise session.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Compare symptoms of fatigue in newly diagnosed acute leukemia patients
Time Frame: participants will be followed for the duration of hospital stay, an expected average of 6 weeks
|
Symptoms will be assessed by patient reported survey at baseline, weekly through patient hospitalization, and then again at patient's first appointment after hospital discharge.
We are interested in how the symptom changes over time.
|
participants will be followed for the duration of hospital stay, an expected average of 6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evaluate health-related quality of life changes over time
Time Frame: participants will be followed for the duration of hospital stay, an expected average of 6 weeks
|
Health related quality of life will be assessed by patient reported survey at baseline, and at the week 4 timepoint.
We are interested in change over time between groups
|
participants will be followed for the duration of hospital stay, an expected average of 6 weeks
|
|
Compare symptoms of anxiety between groups
Time Frame: participants will be followed for the duration of hospital stay, an expected average of 6 weeks
|
Symptoms will be assessed by patient reported survey at baseline, weekly during hospitalization, and at first clinic visit after discharge from hospital.
We are interested in change over time between groups.
|
participants will be followed for the duration of hospital stay, an expected average of 6 weeks
|
|
Compare symptoms of depression between groups
Time Frame: participants will be followed for the duration of hospital stay, an expected average of 6 weeks
|
Symptoms will be assessed by patient reported survey at baseline, weekly during hospitalization, and at first clinic visit after discharge from hospital.
We are interested in change over time between groups.
|
participants will be followed for the duration of hospital stay, an expected average of 6 weeks
|
|
Compare sleep quality between groups
Time Frame: participants will be followed for the duration of hospital stay, an expected average of 6 weeks
|
Symptoms will be assessed by patient reported survey at baseline, weekly during hospitalization, and at first clinic visit after discharge from hospital.
We are interested in change over time between groups.
|
participants will be followed for the duration of hospital stay, an expected average of 6 weeks
|
|
Changes in cardiovascular function
Time Frame: participants will be followed for the duration of hospital stay, an expected average of 6 weeks
|
Exercise testing which will assess the outcome measures will be performed at baseline, and after 4 weeks of training (for the intervention group), or at the week 4 time point (for the control group).
We are interested in change over time between groups.
|
participants will be followed for the duration of hospital stay, an expected average of 6 weeks
|
|
Changes in muscle strength
Time Frame: participants will be followed for the duration of hospital stay, an expected average of 6 weeks
|
Exercise testing which will assess the outcome measures will be performed at baseline, and after 4 weeks of training (for the intervention group), or at the week 4 time point (for the control group).
We are interested in change over time between groups.
|
participants will be followed for the duration of hospital stay, an expected average of 6 weeks
|
|
Changes in body composition
Time Frame: participants will be followed for the duration of hospital stay, an expected average of 6 weeks
|
Exercise testing which will assess the outcome measures will be performed at baseline, and after 4 weeks of training (for the intervention group), or at the week 4 time point (for the control group).
We are interested in change over time between groups.
|
participants will be followed for the duration of hospital stay, an expected average of 6 weeks
|
|
Changes in functional mobility
Time Frame: participants will be followed for the duration of hospital stay, an expected average of 6 weeks
|
Exercise testing which will assess the outcome measures will be performed at baseline, and after 4 weeks of training (for the intervention group), or at the week 4 time point (for the control group).
We are interested in change over time between groups.
|
participants will be followed for the duration of hospital stay, an expected average of 6 weeks
|
|
Changes in muscle size
Time Frame: participants will be followed for the duration of hospital stay, an expected average of 6 weeks
|
Exercise testing which will assess the outcome measures will be performed at baseline, and after 4 weeks of training (for the intervention group), or at the week 4 time point (for the control group).
We are interested in change over time between groups.
|
participants will be followed for the duration of hospital stay, an expected average of 6 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Ashley Bryant, PhD, RN, UNC- Chapel Hill
- Principal Investigator: Claudio Battaglini, PhD, UNC- Chapel Hill
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- LCCC1234
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Leukemia
-
Massachusetts General HospitalCelgene CorporationTerminatedAcute Myelogenous Leukemia | Acute Myeloid Leukemia (AML) | Acute Myelocytic Leukemia | Acute Granulocytic Leukemia | Acute Non-Lymphocytic LeukemiaUnited States
-
National Cancer Institute (NCI)TerminatedAdult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia With Maturation (M2) | Adult Acute Myeloblastic Leukemia Without Maturation... and other conditionsUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Erythroleukemia (M6) | Childhood Acute Megakaryocytic Leukemia (M7) | Childhood Acute Monoblastic Leukemia (M5a) | Childhood Acute Monocytic Leukemia (M5b) | Childhood Acute Myeloblastic Leukemia With Maturation (M2) | Childhood Acute Myeloblastic Leukemia Without Maturation... and other conditionsUnited States
-
Roswell Park Cancer InstituteGlaxoSmithKlineTerminatedRecurrent Adult Acute Myeloid Leukemia | Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia With Maturation (M2) | Adult Acute... and other conditionsUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Monoblastic Leukemia (M5a) | Childhood Acute Monocytic Leukemia (M5b) | Childhood Acute Myeloblastic Leukemia Without Maturation (M1) | Childhood Acute Myelomonocytic Leukemia (M4) | Childhood Acute Myeloid Leukemia/Other Myeloid MalignanciesUnited States
-
National Cancer Institute (NCI)Active, not recruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Adult Acute Monoblastic Leukemia | Adult Acute Monocytic Leukemia | Adult Acute Myeloid Leukemia With Maturation | Adult Acute Myeloid Leukemia Without Maturation | Adult Acute Myelomonocytic Leukemia | Alkylating Agent-Related Acute Myeloid... and other conditionsUnited States
-
National Cancer Institute (NCI)TerminatedAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia in Remission | Adult Acute Monoblastic Leukemia | Adult Acute Monocytic Leukemia and other conditionsCanada
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedAdult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia With Maturation (M2) | Adult Acute Myeloblastic Leukemia Without Maturation... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedAdult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia With Maturation (M2) | Adult Acute Myeloblastic Leukemia Without Maturation... and other conditionsUnited States
-
Nohla Therapeutics, Inc.National Cancer Institute (NCI); Fred Hutchinson Cancer CenterCompletedRecurrent Adult Acute Myeloid Leukemia | Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia With Maturation (M2) | Adult Acute... and other conditionsUnited States
Clinical Trials on Exercise
-
National Institute of Neurological Disorders and...TerminatedTraumatic Brain InjuryUnited States
-
University of Texas, El PasoRecruitingKnee Osteoarthritis | Knee Pain Chronic | Central Pain SyndromeUnited States
-
Aksaray University Training and Research HospitalCompletedExercise Training | Lactate Blood Increase | Cognitive Functions | BDNFTurkey (Türkiye)
-
University of Alabama at BirminghamCompletedCystic FibrosisUnited States
-
University of LisbonFundação para a Ciência e a TecnologiaActive, not recruiting
-
University of Missouri-ColumbiaCompleted
-
University of AlcalaCompletedMyofascial Pain | Myofascial Pain Syndrome | Post Needling Soreness | Myofascial Trigger Point PainSpain
-
Toronto Rehabilitation InstituteCompletedAcute Myeloid LeukemiaCanada
-
University College CorkRecruitingDepressive Disorder, MajorIreland
-
Sahmyook UniversityRecruitingChronic Nonspecific Neck PainKorea, Republic of